Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IBI129 in advanced solid tumors
CTR20240916Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI-129 in Nonhematologic neoplasms, small cell lung cancer (SCLC), prostate cancer (PCa), sponsored by InnoCare Pharma. Started Mar 2024; status: completed.
02
Drugs
IBI-129
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20240916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240916.